Barclays’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-5
| Closed | – | – | 7669 |
|
|
2018
Q1 | $0 | Buy |
+5
| New | +$5 | ﹤0.01% | 7669 |
|
|
2017
Q4 | – | Sell |
-100
| Closed | – | – | 7397 |
|
|
2017
Q3 | $0 | Hold |
100
| – | – | ﹤0.01% | 7342 |
|
|
2017
Q2 | $0 | Hold |
100
| – | – | ﹤0.01% | 7293 |
|
|
2017
Q1 | $0 | Sell |
100
-3,684
| -97% | -$14.5K | ﹤0.01% | 7285 |
|
|
2016
Q4 | $6K | Buy |
3,784
+3,527
| +1,372% | +$8.29K | ﹤0.01% | 6117 |
|
|
2016
Q3 | $0 | Sell |
257
-2,476
| -91% | -$9.35K | ﹤0.01% | 7107 |
|
|
2016
Q2 | $12K | Buy |
2,733
+1,304
| +91% | +$5.9K | ﹤0.01% | 5491 |
|
|
2016
Q1 | $0 | Sell |
1,429
-611
| -30% | -$7.93K | ﹤0.01% | 6892 |
|
|
2015
Q4 | $20K | Sell |
2,040
-11,918
| -85% | -$284K | ﹤0.01% | 5198 |
|
|
2015
Q3 | $279K | Buy |
13,958
+11,447
| +456% | +$392K | ﹤0.01% | 3858 |
|
|
2015
Q2 | $100K | Buy |
2,511
+1,138
| +83% | +$68K | ﹤0.01% | 4675 |
|
|
2015
Q1 | $97K | Sell |
1,373
-118
| -8% | -$7.32K | ﹤0.01% | 4875 |
|
|
2014
Q4 | $89K | Sell |
1,491
-8,316
| -85% | -$418K | ﹤0.01% | 5304 |
|
|
2014
Q3 | $393K | Sell |
9,807
-8,023
| -45% | -$431K | ﹤0.01% | 4167 |
|
|
2014
Q2 | $1.07M | Buy |
17,830
+13,202
| +285% | +$768K | ﹤0.01% | 3265 |
|
|
2014
Q1 | $278K | Sell |
4,628
-5,960
| -56% | -$403K | ﹤0.01% | 4479 |
|
|
2013
Q4 | $529K | Buy |
10,588
+3,789
| +56% | +$213K | ﹤0.01% | 4040 |
|
|
2013
Q3 | $408K | Buy |
6,799
+3,264
| +92% | +$221K | ﹤0.01% | 4338 |
|
|
2013
Q2 | $206K | Buy |
+3,535
| New | +$217K | ﹤0.01% | 5149 |
|
Other funds holding OREX
Barclays's OREX Position: Q2 2018 in Review
Barclays sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 5 shares.
Barclays first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $1.07M in Q2 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Barclays reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Barclays sold 5 Orexigen Therapeutics, Inc. shares in Q2 2018.
- Barclays first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Orexigen Therapeutics, Inc. position peaked at $1.07M in Q2 2014.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.